PAA
BMRN icon

Peregrine Asset Advisers’s BioMarin Pharmaceuticals BMRN Stock Holding History

Peregrine Asset Advisers’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-3,000
Closed -$279K – 106
2017
Q3 		$279K Hold
3,000
– – 0.15% 67
2017
Q2 		$272K Hold
3,000
– – 0.17% 66
2017
Q1 		$263K Hold
3,000
– – 0.14% 70
2016
Q4 		$249K Hold
3,000
– – 0.15% 88
2016
Q3 		$278K Buy
+3,000
New +$282K 0.17% 84

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Peregrine Asset Advisers's BMRN Position: Q4 2017 in Review

Peregrine Asset Advisers sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2017, closing a stake of 3,000 shares — an estimated $279K sold.

Peregrine Asset Advisers first reported a position in BMRN in Q3 2016 and held it in 5 quarters. The position peaked at $279K in Q3 2017. 438 funds tracked by Wall St. Rank hold BMRN as of Q4 2017.

  • Peregrine Asset Advisers reported no remaining BioMarin Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Peregrine Asset Advisers sold 3,000 BioMarin Pharmaceuticals shares in Q4 2017, an estimated $279K.
  • Peregrine Asset Advisers first reported a position in BioMarin Pharmaceuticals in Q3 2016 and held it in 5 quarters.
  • Peregrine Asset Advisers's BioMarin Pharmaceuticals position peaked at $279K in Q3 2017.
  • 438 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2017.

Based on Peregrine Asset Advisers's 13F filing for Q4 2017, filed 1 Feb 2018.